Clinical Trial Update: Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy [Phase 2]

View source ↗

Summary

Phase 2 trial completed evaluating three ultra-low-dose estriol vaginal gels for vaginal dryness in postmenopausal women with vulvovaginal atrophy; results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Vaginal Dryness
• Vaginal Atrophy

Drugs mentioned

• Ultra-low dose estriol vaginal gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) (estriol vaginal gel)

Snippet

Sponsor: ITF Research Pharma, S.L.U. | Conditions: Vaginal Atrophy | Phase 2 | Status: COMPLETED | Results posted: 2019-09-25